Publications by authors named "Irving Fox"

Claim this Profile
A
A Programme for Risk Assessment and Minimisation of Progressive Multifocal Leukoencephalopathy Developed for Vedolizumab Clinical Trials.
Asit Parikh, Kristin Stephens, Eugene Major, Irving Fox, Catherine Milch

Drug Saf· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum: Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease.
Maria Rosario, Jonathan L French, Nathanael L Dirks, Serap Sankoh, Asit Parikh, Irving Fox

J Crohns Colitis· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab.
Maria Rosario, Nathanael L Dirks, Catherine Milch, Asit Parikh, Michael Bargfrede, Irving Fox

Clin Pharmacokinet· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease.
Maria Rosario, Jonathan L French, Nathanael L Dirks, Serap Sankoh, Asit Parikh, Irving Fox

J Crohns Colitis· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The safety of vedolizumab for ulcerative colitis and Crohn's disease.
Jean-Frédéric Colombel, Bruce E Sands, Paul Rutgeerts, William Sandborn, Silvio Danese, Irving Fox

Gut· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Polymalic Acid Tritryptophan Copolymer Interacts with Lipid Membrane Resulting in Membrane Solubilization.
Hui Ding, Irving Fox, Rameshwar Patil, Anna Galstyan, Keith L Black

J Nanomater· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER2-positive breast cancer targeting and treatment by a peptide-conjugated mini nanodrug.
Hui Ding, Pallavi R Gangalum, Anna Galstyan, Irving Fox, Rameshwar Patil

Nanomedicine· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme.
Szu-Ting Chou, Rameshwar Patil, Anna Galstyan, Pallavi R Gangalum, Webster K Cavenee, Irving Fox

J Control Release· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vedolizumab Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability Following Administration of a Single, Ascending, Intravenous Dose to Healthy Volunteers.
Maria Rosario, Timothy Wyant, Timothy Leach, Serap Sankoh, Catherine Scholz, Irving Fox

Clin Drug Investig· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Occurrence of adverse events among patients with inflammatory bowel disease in the HealthCore Integrated Research Database.
Megan E McAuliffe, Stephan Lanes, Timothy Leach, Asit Parikh, Gerald Faich, Irving Fox

Curr Med Res Opin· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.
Bruce E Sands, Brian G Feagan, Paul Rutgeerts, Jean-Frédéric Colombel, William J Sandborn, Irving Fox

Gastroenterology· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vedolizumab, a monoclonal antibody to the gut homing α4β7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype.
Catherine Milch, Tim Wyant, Jing Xu, Asit Parikh, Whitney Kent, Irving Fox

J Neuroimmunol· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vedolizumab as induction and maintenance therapy for ulcerative colitis.
Brian G Feagan, Paul Rutgeerts, Bruce E Sands, Stephen Hanauer, Jean-Frédéric Colombel, Irving Fox

N Engl J Med· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vedolizumab as induction and maintenance therapy for Crohn's disease.
William J Sandborn, Brian G Feagan, Paul Rutgeerts, Stephen Hanauer, Jean-Frédéric Colombel, Irving Fox

N Engl J Med· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease.
Asit Parikh, Irving Fox, Timothy Leach, Jing Xu, Catherine Scholz

Inflamm Bowel Dis· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study.
Asit Parikh, Timothy Leach, Tim Wyant, Catherine Scholz, Serap Sankoh, Irving Fox

Inflamm Bowel Dis· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.
Brian G Feagan, Gordon R Greenberg, Gary Wild, Richard N Fedorak, Pierre Paré, Irving H Fox

N Engl J Med· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis